DEENOVA
20.6.2022 06:02:09 CEST | Business Wire | Press release
Deenova today disclosed that it expanded its market dominance in France with another net new UniHA competitive award for its D3 ACCED mechatronic solution at Centre Hospitalier de Mayotte in French overseas departments. Additionally, Deenova announced a new competitive tender win at GHPSO Creil & Senlis also for its market leading D3 ACCED mechatronic robot through its partnership with another premier hospital group, RESAH . Separately, Deenova is pleased to simultaneously report additional add-on sales of its unique ASTUS cabinets and D3 ACCED to existing Deenova customer Institute Nationale des Invalides in Paris, also through its UniHA partnership.
Loïc Bessin , Managing Director of Deenova in France stated: “Bringing together net new business tender wins at Centre Hospitalier de Mayotte and GHPSO Creil & Senlis for our D3 ACCED mechatronic solutions, while at the same time earning the trust of additional sales to previous Deenova ASTUS customers such as Institute Nationale des Invalides is steady evidence of Deenova France unparalleled success in our industry, undoubtedly showing the market a high level of reliable customer satisfaction in France.”
Christophe Jaffuel , Deenova Chief Commercial Officer, added: “A new milestone for Deenova is reached: expansion beyond the European continent, a great ongoing incentive for our sales teams. I am very appreciative for the important and yearly contribution that both UniHA and RESAH ongoing multi-year tender awards means to Deenova in France and now beyond, renewing its past commitment to Deenova market-leading Unit-Dose solutions. I look forward to continuing the outstanding cooperation with UniHA and RESAH in the near future.”
Centre Hospitalier de Mayotte , a public health establishment with 543 beds, is the only hospital in the overseas Department of Mayotte . It is located in the northern part of the Mozambique Channel in the Indian Ocean off the coast of Southeastern Africa. It provides both hospital care and out-patient care with 4 localized care and childbirth centers (North, Centre, South and Petite-Terre) of intermediate level, providing general consultations and a 24-hour medical service and 7 days a week.
GHPSO Creil & Senlis , located just 30 minutes from Paris CDG airport , offers a complete emergency service: Adult, Paediatric and Gyneco-obstetrics with 584 full hospital beds, 46 day hospitalization places, 21 haemodialysis stations, and on the other hand an offer in Follow-up and Rehabilitation Care (SSR) with 32 beds, in accommodation with 73 Long-Term Care Unit beds (USLD), 90 beds in an Accommodation Establishment for Dependent Elderly Persons (EHPAD) and 12 places in Alzheimer's day centre, i.e. a total of 858 beds. The SMUR unit intervenes at the request of the SAMU de l’Oise.
Institute Nationale des Invalides is placed under the supervision of the French Government Ministry of Defense and Veterans Affairs. It is responsible for welcoming veterans who are victims of severe handicaps linked to war wounds. It includes three complementary centers: the Pensioners’ Center, the Post-Traumatic Rehabilitation Center and the Center for Studies and Research on Equipment for the Handicapped. A total of 91 single rooms are fully equipped for patients in the Paris metropolitan area.
UniHA , the Union of Hospitals for Purchasing, is a cooperative of French public hospital buyers created in 2005 by the hospital staff themselves (32 CHU and 20 CH). As of 2022, 1.065 hospitals have joined the UniHA cooperative, with 115 GHT having conducted € 5.6 billion in group purchases in 2021. UniHA is one of the main European buyers in the field of health and one of the first national buyers, all sectors of activity combined. The essential challenge: to provide citizens with the best treatments available, to provide high-quality hospital services, and to preserve equal access to care.
RESAH is a public interest group (GIP) whose objective is to support the pooling and professionalisation of purchases from the health sector, public and private non-profit. It was created in 2007 to support the pooling of hospital purchases for the Ile-de-France region, in collaboration with Achat Hopital.
Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova ’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%. Please visit www.deenova.com for additional information on its market leading solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220619005038/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release
This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living
Swiss Leader Leonteq Chooses ActiveViam to Deliver High‑Performance FRTB Risk Analytics10.2.2026 09:00:00 CET | Press release
ActiveViam, a global leader in real‑time, multidimensional risk analytics for capital markets, today announced that Leonteq, one of the leading Swiss providers of structured products, has implemented Atoti to calculate Market Risk Capital Charges under the Standardized Approach of the Fundamental Review of the Trading Book (SA-FRTB). ActiveViam’s flagship product, Atoti, is being used by Leonteq as its FRTB reporting solution to the Swiss Financial Market Supervisory Authority (FINMA). Switzerland implemented FRTB for its banks on 1st January 2025 and FINMA recently extended its scope to include Leonteq. When the FRTB implementation deadlines became clear, Leonteq evaluated several vendors for a solution that could integrate with its existing pricing engines. After a detailed assessment, it selected Atoti. The solution provides dashboards and preconfigured reports that meet FINMA’s requirements, along with analytics aligned to the ISDA Unit Tests and additional capabilities such as wha
Bending Spoons offers €1.5 million in tech scholarships through new Fellowship program10.2.2026 09:00:00 CET | Press release
Today Bending Spoons announced the launch of the Bending Spoons Fellowship, committing up to €1.5 million to support Europe’s most outstanding computer science students through the program. The fellowship will award ten scholarships—each worth €50,000 per year and renewable for up to three years—to high-achieving university students in computer science and related fields across Europe and the UK. “We think exceptional talent deserves exceptional opportunities,” said Costanza Mazzei, the Bending Spoons talent manager leading the program. “With the Bending Spoons Fellowship, we aim to give Europe’s most driven students the freedom, resources, and guidance to reach the highest levels of excellence.” In addition to financial support, Fellowship participants will benefit from individual mentorship and may choose to participate in an optional paid summer internship at Bending Spoons. The fellowship is the latest initiative from Bending Spoons to support emerging technical talent. It builds o
Ralph Haupter Joins Warburg Pincus as an External Senior Advisor10.2.2026 09:00:00 CET | Press release
Seasoned Technology Executive to Support European Technology Group Warburg Pincus, the pioneer of private equity global growth investing, today announced that Ralph Haupter will serve as an External Senior Advisor to its European Technology team. Mr. Haupter, Executive Vice President and Chief Revenue Officer for Small Medium Enterprises and Channel (SME&C) at Microsoft, will take on this personal engagement to help the firm identify and evaluate new investment opportunities across the software and technology sectors. He will also play an active role in value creation across the firm’s existing portfolio. Mr. Haupter brings over 25 years of global operating experience and deep expertise in technology innovation and transformation. At Microsoft, he leads a global organization that works with the company’s extensive partner ecosystem to empower small and medium businesses worldwide. Previously, he held senior leadership roles across Europe, Asia, and the Americas, including President of
CapVest Enters Exclusive Discussions With HLD on the Proposed Acquisition of TSG10.2.2026 09:00:00 CET | Press release
HLD and management to retain significant minority stakes in TSG, partnering with CapVest on a shared vision to lead the company into its next phase of global growth CapVest Partners LLP (“CapVest”), a leading New York and London based investment firm, and HLD, the entrepreneurial European investment group, have entered exclusive discussions on CapVest’s proposed acquisition of a majority stake in TSG, a European leader in technical services for critical energy infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210375858/en/ Headquartered in Paris, France, TSG is a European leader in technical services for the energy industry with a pan-European footprint in over 30 countries and employing over 7,000 people. Originally focused on fuel station and private fleet energy infrastructure and systems, since HLD’s acquisition of the company in 2020 TSG has undergone significant transformation as a primary enabler of th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
